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Summary
The bar is high to improve on current combination antiretroviral therapy (ART), now highly 
effective, safe, and simple. However antibodies that bind the HIV envelope are able to uniquely 
target the virus as it seeks to enter new target cells, or as it is expressed from previously infected 
cells. Further, the use of antibodies against HIV as a therapeutic may offer advantages. Antibodies 
can have long half-lives, and are being considered as partners for long-acting antiretrovirals for use 
in therapy or prevention of HIV infection. Early studies in animal models and in clinical trials 
suggest that such antibodies can have antiviral activity but, as with small molecule antiretrovirals, 
the issues of viral escape and resistance will have to be addressed.
Most promising, however, are the unique properties of anti-HIV antibodies: the potential ability to 
opsonize viral particles, to direct antibody-dependent cellular cytotoxicity (ADCC) against 
actively infected cells, and ultimately the ability to direct the clearance of HIV-infected cells by 
effector cells of the immune system. These distinctive activities suggest that HIV antibodies and 
their derivatives may play an important role in the next frontier of HIV therapeutics, the effort to 
develop treatments that could lead to an HIV cure.
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An examination of the lifecycle of HIV-1 informs the discussion of new approaches to 
antiretroviral therapy (ART), in the context of the array of small molecule inhibitors that 
already provide remarkably effective treatment for HIV-1 infection. HIV infection is 
characterized by cycles of virus production and reinfection, a process that occurs optimally 
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within activated CD4+ T lymphocytes. Viral expression begins with the transcription and 
translation of early, regulatory viral gene products from the integrated proviral genome 
within the infected cell. This leads to a cascade of expression of late, structural viral 
proteins, and the assembly and budding of infectious viral particles (1).
Virions then spread within the host to infect new, susceptible target cells. The process of 
infection can occur directly by cell-to-cell spread in vitro, but how often this occurs in vivo 
is unknown (2). Predominantly, HIV particles enter new host cells via direct contact across 
the “immunological synapse” of an infected cell apposed to a target cell, or once the budded 
virion has travelled free from the producer cell. In either case, the HIV particle first engages 
the CD4 receptor in a weak interaction with the HIV envelope glycoprotein that docks the 
virion at the target cell. Then a second interaction of HIV envelope with a cellular 
chemokine receptor, principally the CCR5 receptor, induces a conformation shift in the HIV 
envelope structure that allows a fusion event to occur between the viral and cellular 
membranes (3).
Viral fusion with the target cell membrane then allows the deposition of the viral 
nucleocapsid within the newly infected cell, which delivers the HIV genome in its RNA 
form, along with molecules of HIV reverse transcriptase (RT) and integrase, in the cellular 
cytoplasm. HIV RT then co-opts cellular nucleosides and directs transcription of viral RNA 
into double-stranded linear DNA copies of the HIV genome. Viral integrase then forms a 
pre-integration complex with the HIV DNA and travels through nuclear pores to find a site 
for integration into the host genome. This is a vulnerable time for the infection process, as 
reverse transcription of the HIV genome must be complete and accurate in the face of the 
host apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (ApoBEC) factors, 
which induce hypermutation of the incoming viral RNA genome as it is reversed transcribed 
in to viral DNA. Further, the new viral DNA genome must rapidly achieve successful 
integration before it falls prey to degradation by host nucleases, or anneals in an auto-
ligation event that recreates a dead-end circular viral genome.
HIV infection is then irreversibly established within the new target cell by a surviving viral 
genome that has entered the host genome without being marked by lethal hypermutation. 
Viral gene expression may then proceed in the cascade that leads to production of a new 
swarm of virions, or the viral genome may lapse in to a state of latency. Overall, while the 
establishment of durable viral latency is a rare event, and robust viral expression may ensue 
in most cells immediately following infection, a significant number of newly infected cells
—perhaps those infected while in a less activated state—may express viral particles after a 
delay or over a prolonged period of time (4).
Viral replication leads, directly or indirectly, to the loss of CD4+ T cells and immune 
dysfunction. Poised to interrupt this relentless process that gradually leads to fatal 
immunodeficiency in most infected humans, is an arsenal of more than three dozen Food and 
Drug Administration–approved drugs and co-formulations available for treatment of HIV-1 
infection. These small molecule antiretroviral drugs can be divided into classes based on 
their antiviral molecular mechanism: (1) nucleoside-analog and non–nucleoside-analog 
reverse transcriptase inhibitors (NRTIs and NNRTIs), (2) integrase inhibitors, (3) protease 
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inhibitors, (4) fusion inhibitors, and (5) coreceptor antagonists. The vast majority of HIV-
infected people on ART around the world receive combination therapy using drugs from the 
first three classes that target the viral RT, integrase, or protease enzymes. These widely used 
inhibitors target the HIV lifecycle after viral entry and before viral particles are expressed 
(NNRTIs, NRTIs, and integrase and protease inhibitors).
Once combination ART (cART) is employed in a combination potent enough to ablate 
ongoing viral replication and prevent the emergence of drug resistance, an event documented 
clinically by the suppression of plasma viremia to fewer than 50 copies of HIV-1 RNA/µl, 
immune recovery often ensues, and AIDS-related clinical events become rare. The ongoing 
implementation of ART throughout the world has been one of the greatest success stories of 
modern medicine. However, current ART has burdens that include the cost of drugs and 
medical care, adherence to lifelong therapy, the potential for the emergence of drug-resistant 
HIV if adherence is not maintained, and the potential long-term toxicities of small-molecule 
drugs.
It is in this context that we may consider the possible benefits and challenges of humoral 
ART using broadly neutralizing anti-HIV antibodies (bnAbs). Therapy with bnAbs uniquely 
targets the viral lifecycle at its two poles: viral entry and viral particle expression (Figure 1). 
Of note, these two stages of HIV-1 lifecycle can be targeted by monoclonal antibodies 
(mAbs) recognizing the CD4 inducible (CD4i) constant region 1 and 2 (C1/C2) and the 
gp41 cluster I region that are non-neutralizing Abs (non-nAb) and that will be further 
described below. Therefore, both bnAbs and non-nAbs can be used to generate molecules 
that can target infected cells. While fusion inhibitors and coreceptor antagonists block viral 
entry, these drugs have thus far found limited use in the clinic. Fusion inhibitors have not 
gained traction in the clinic largely due to manufacturing cost and the challenges of frequent 
subcutaneous injection required for their use. Coreceptor antagonists, mAbs, and mAb-based 
molecules share the potential benefit of blocking infection at an early stage, which prevents 
the transcription of viral DNA or viral proteins within the target cells, though clinical data 
has yet to bear this out.
As biologics, mAbs-based therapeutics might spare HIV-infected patients the risk of long-
term end-organ toxicities, although antibody therapy may be accompanied by long-term 
risks as yet unappreciated. Further, as mAbs and their derivatives may be engineered to have 
very durable pharmacokinetic profiles, or even be delivered via cellular or genetic therapies, 
they have the potential to ameliorate the challenges of lifelong adherence to therapy 
administration (5). However, as will be discussed in detail, bnAbs will have to contend with 
the capacity of HIV to evolve resistance to therapeutic agents, in this case via the same 
plasticity of HIV envelope structure that allows the virus to escape the antiviral immune 
response. So, like standard antiretrovirals, mAbs will most likely have to be administered as 
carefully tested, effective combinatorial therapy.
Persistent HIV infection despite effective ART
HIV-1 infection remains incurable despite the maintenance of viremia suppression, the 
prevention of drug resistance, and durable clinical benefits of standard ART. Persistent HIV 
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infection despite ART is also marked by mild but persistent abnormalities of the immune 
system, and bnAbs might contribute to efforts to eradicate infection, or more fully resolve 
the effects of HIV infection on immune function.
Latent and persistent infection by a small population of quiescent, replication-competent 
proviruses is founded within a long-lived population of memory T cells, capable of 
reigniting new rounds of infection if therapy is interrupted. This latent pool of virus is 
established within days of infection and is unaffected by the antiviral immune response or 
current therapy (6,7). The latent pool is maintained in part by the quiescent state of the 
infected cell, the enforcement of proviral latency by host cellular factors, and the long 
lifespan of such cells. Homeostatic proliferation of latently infected cells may also 
contribute to latent infection (8,9). HIV DNA integrants are enriched in or near host genes 
associated with cell cycle control, suggesting that the integration of HIV-1 into such sites 
could lead to proliferation of these latently infected cells (10,11). Although one study 
examining a limited number of integrants suggests that these proliferating integrants are 
defective (12), a recent clinical observation calls this conclusion into question (13). Should 
rare latently infected cells transiently display viral proteins while undergoing proliferation, 
anti-HIV antibodies with antibody-dependent cell-mediated cytotoxic (ADCC) activity 
could allow clearance of these persistently infected cells. Indeed, some evidence suggests 
that residual viremia observed with suppressive ART may originate from viral species in the 
resting CD4+ T cell reservoir (14).
The potential contribution of residual virus replication despite ongoing ART remains 
controversial in some quarters. Multiple controlled studies of therapy intensification have 
failed to demonstrate an effect of any of the current antiretroviral agents on low-level 
viremia, suggesting that such viremia is generated by cells infected prior to the 
implementation of therapy, and not through residual replication (15–21). Two studies of 
integrase inhibitor intensification found transient changes in forms of HIV 2-LTR DNA or 
reductions in immune activation (22,23). And one study found HIV sequence evolution 
within lymph node tissue in patients treated for 6 months (24), a relatively short period of 
time after initiating ART. However, other studies found no evidence of viral evolution in 
plasma or tissues following years of suppression of viremia (25,26). If bnAbs can provide a 
novel and additional antiviral effect, acting at a novel step of the viral lifecycle and/or 
possessing unique pharmacokinetic properties, residual replication—if it exists—might be 
impacted.
HIV bnAbs as therapy for cure or control
In addition to increasing the efficacy, safety, and ease of administration of current ART, 
bnAbs have the potential to extend beyond the therapeutic potential of small molecule 
inhibitors of viral targets. Antibodies differ from small-molecule drugs that interfere with 
viral replication in that antibodies have the potential to affect the half-lives of both free virus 
and infected cells. As part of a novel combination approach to disrupt latency and clear 
persistent infection now under expanded study in several research groups, bnAbs could play 
a role in inducing the clearance of infected cells—both recently infected cells and long-lived 
latently infected cells. The goal of such approaches would first be the induction of a state of 
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viral remission -- defined as the absence of viremia, infectiousness, and immune dysfunction 
despite the interruption of standard ART -- and, ultimately, the cure of HIV infection.
Clearing residual HIV infection that remains despite effective and prolonged suppression of 
viral replication by ART presents a unique challenge for the immune system and 
immunotherapeutics. In the current paradigms of therapies to disrupt latency and clear 
persistent infection, the targets for clearance are rare populations of cells, induced to express 
HIV proteins by a new class of therapeutic termed latency reversing agents. These latently 
infected cells may also express viral antigens for a very limited period of time, and in low 
quantity, presenting a challenge to any native or engineered immune response.
Following the reactivation of latent HIV, viral antigens are presented on the surface of the 
cell and thus could be targeted by antibodies or antibody-derived molecules. Immunotoxins, 
which are bifunctional chimeric proteins consisting of a targeting portion, such as an 
antibody or a ligand, and a toxin effector domain, have provided proof of concept for this 
approach (27). Initial clinical trials in HIV disease using immunotoxins failed to have a 
sustained impact on immunological or clinical markers (28), likely due in part to the 
inability to recognize a breadth of Env targets. In the bone-marrow-liver (BLT) humanized 
mouse model an immunotoxin effectively eliminated HIV-infected cells persisting despite 
ART (29).
BnAbs have by definition exceptional breadth across multiple viral isolates. As will be 
discussed in detail in the following sections, bnAbs have been shown to be potent in vitro, 
and can protect against or suppress active infection in animal models of HIV infection (30–
32,34). Recently, one bnAbs were shown to have antiviral activity in phase I human clinical 
trials (35, 58). BnAb-mediated immunotherapies may leverage the activity of the host 
immune system, bringing to bear both innate and adaptive immune responses (36). As 
antibodies interact via Fc receptors on natural killer (NK) cells and phagocytes, these 
effector cells may then mediate the clearance of infected cells (37). Furthermore, these 
infected cell populations may be widely distributed across anatomical compartments, and in 
many patients the HIV-specific immune response may have waned in the absence of recent 
antigen exposure, and/or may be dysfunctional or depleted by HIV disease. Therefore, a 
novel and robust immune response may be necessary to detect and clear cells producing low-
level viremia, and quiescently infected cells induced to leave the latent state. In this setting, 
bnAbs, particularly those that also had or were engineered to possess ADCC activity, may be 
of great value.
In vivo evidence for antiretroviral activity of bnAbs
The preceding sections detail the compelling rationale for why bnAbs would have an in vivo 
antiviral effect and should be tested for such activity. One approach to assess bnAb activity 
in vivo is to compare the level of viremia and the speed of viral escape from bnAbs in 
individuals who have, or have not, generated bnAbs during natural HIV infection. Seminal 
studies from the 1990s showed that serum from most HIV-infected subjects failed to 
substantially neutralize the concurrent virus circulating in plasma (38,39). Studying subjects 
longitudinally from seroconversion further demonstrated that autologous serum virus 
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neutralization could occur early after infection, but was always accompanied by rapid escape 
and replacement of the viral quasispecies by viruses resistant to autologous serum 
neutralization, and there were minimal to no discernable changes in viral load associated 
with these changes (38–42). More recent data indicate that broad serum neutralization in 
chronic infection is associated with higher, rather than lower, viral loads, and is further 
characterized by evidence of ongoing virus escape from the neutralizing Ab (nAb) response 
(43–45). While some have posited a lack of inverse correlation between serum nAb activity 
and plasma viral load as evidence for absent in vivo antiviral activity of serum neutralizing 
antibodies, the evidence for rapid viral escape from the nAb response in all of the studies 
argues for exactly the opposite: bnAbs have a direct antiviral effect on replicating virus, 
which serves as the selecting pressure for escape. If the antibodies were not detrimental to 
circulating virus, there would be no evidence of escape. Collectively, the data suggest that 
the virus can always stay a step ahead of the nAb response during natural infection, probably 
because of a low barrier to resistance of the virus to each subsequent broadening mutation in 
the antibody repertoire. The question then becomes whether exogenously administered 
bnAbs can more effectively inhibit virus replication than nAbs that develop naturally in 
response to virus escape. Multiple studies in animal models and human clinical trials have 
begun to address these questions.
Humanized mouse studies
Initial experiments to test the in vivo therapeutic effect of bnAbs were carried out in 
humanized mice, and demonstrated only limited antiviral effect (46,47). This is probably due 
to several factors. First, the nAbs used in early studies (b12, 2F5, 2G12) were not nearly as 
potent or broad as more recently described bnAbs. Second, the Hu-PBL-SCID model shows 
generally greater variability in HIV replication than some of the more sophisticated mouse 
models that incorporate human stem cells, thymus, and/or liver tissues in reconstituting the 
mice. As a result, single nAb therapy was generally ineffective in Hu-PBL-SCID mice 
(46,47), though combinations of nAbs occasionally led to sustained viral suppression. In the 
majority of cases, however, viral suppression by nAbs—if it occurred—was transient and 
associated with the rapid selection of viruses that escaped the MAb therapy. These early 
studies gave a good indication that neutralizing nAbs could have an antiviral effect in vivo, 
but that the barrier to resistance (at least to early nAbs) was low.
With the description of more bnAbs, it became important to test them for antiviral activity in 
vivo, and humanized mice were the most easily accessible models. These recent studies have 
incorporated more physiologic humanized mouse models than were used in earlier studies 
(30,48,49). The collective findings show that when there is adequate potency of a nAb 
against the circulating strain of HIV, there will be a measurable effect on viral replication; 
the more potent the antibody, the more substantial the antiviral effect (30). The barrier to 
resistance also was found to be important. In general single antibodies had no or only 
transient effects on virus replication, where combinations of antibodies proved to have a 
more persistent antiviral effect and prolonged time to resistance development (30,48,49). 
While none of the studies addressed the mechanism of the antiviral effect, a recent study 
where HIV-infected cells were infused into humanized mice, in the presence or absence of 
bnAbs, suggests that enhanced clearance of virus-infected cells is one possible mechanism 
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by which bnAbs exert their antiviral effect in vivo (37). This latter finding suggests that 
efforts to improve effector function of existing bnAbs may lead to improved antiviral effects.
Nonhuman primate studies
A number of experiments assessing the in vivo antiviral activity of bnAbs have been 
performed in nonhuman primates (NHP). Initial studies using the anti-CD4 mAb 5A8 
showed an antiviral effect in monkeys infected with simian immunodeficiency virus 
(SIVmac), but were limited by the rapid development of anti-mouse antibodies within 
monkeys to whom 5A8 was passively administered (50,51). In contrast, more recent studies 
with human bnAbs have shown rather dramatic antiviral effects of individual and 
combinations of passively administered antibodies (33,34) in simian/human 
immunodeficiency virus (SHIV)–infected monkeys. Antiviral effects in excess of 3 logs of 
plasma virus suppression were seen, and the virus tended to rebound after antibody 
concentrations dropped, though in some monkeys with low baseline plasma virus load, 
persistent viral suppression was observed even after antibody levels dropped below a 
therapeutic concentration (33). SHIV resistance to antibodies to the glycan V3 site 
developed in monkeys given 10–1074 (34) but not PGT121 (33), possibly reflecting 
different barriers to resistance to these two antibodies in vivo. While Barouch et al observed 
a sharp decline in cell-associated cellular SHIV DNA during antibody therapy (33), this 
should not be interpreted as indicating a direct effect of the bnAbs in killing of SHIV-
infected cells. Standard ART in humans also leads to a decline in cell-associated viral DNA, 
reflecting the fact that most viral replication in vivo occurs in recently activated and infected 
CD4 T cells that express proviral DNA as part of the viral life cycle (52,53).
The substantial antiviral effect of bnAbs in NHPs raises the question of whether they would 
be an effective adjunctive therapy in a cure strategy. Early therapy during acute infection has 
been shown to limit the development of the latent reservoir, thereby decreasing the barrier to 
cure (54). A study was therefore performed to determine if bnAbs would have an impact on 
virus load during acute infection, and whether this would further reduce the latent reservoir 
over what ART alone could accomplish (55). NHPs were treated with a single bnAb 
(VRC01), a combination of bnAbs (VRC07-523 and PGT121), or ART alone starting 10 
days after IV infection with SHIV162P3. At 21 days, monkeys in all three arms received 
ART. The antiviral effect in the combination bnAb arm was identical to the ART alone arm, 
and there was no difference in time to full viral suppression, cell-associated DNA, or time to 
rebound when ART was stopped. These data suggest that bnAb therapy, at least during acute 
SHIV infection, does not have a greater effect on the latent reservoir than ART alone.
Human clinical trials
The true antiviral effect of bnAbs will be determined in human clinical trials, several of 
which have already occurred. In an attempt to determine the direct antiviral effect of bnAbs 
on HIV replication, bnAbs have been given to several HIV-infected individuals not on ART, 
and the impact on virus replication has been measured. The initial studies to look for a direct 
antiviral effect of antibodies in humans were performed with the anti-CD4 molecule 
ibalizumab (56,57). Only a modest (up to 1 log) and transient decrease in plasma viremia 
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was observed before antiviral resistance arose. In two more recent studies that tested CD4 
binding site (CD4bs) mAbs (3BNC117 and VRC01), they were shown to have a greater, but 
mostly still transient, effect on plasma virus load (approximately 1–2.5 log decrease) 
(35,58). While subjects with low baseline plasma virus loads had more sustained viral 
control, the selection of MAb-resistant variants was variable. Subjects with pre-existing 
resistance had little to no antiviral response. Among individuals with sensitive virus 
quasispecies, resistance frequently became apparent as the virus load rose before plasma 
antibody levels declined to sub-therapeutic levels (58). Some individuals, however, 
maintained viral suppression until antibody levels dropped, and the rebounding virus 
remained sensitive to the infused bnAb (35).
Another way to assess the antiviral effect of bnAbs is to assess their ability to maintain virus 
suppression in individuals whose virus replication is already suppressed by ART, but who 
undergo an analytic treatment interruption. In this setting there may be minimal virus 
replication initially, and it may therefore be less likely that resistance to the bnAb(s) will 
arise. In the first studies to test this approach, a cocktail of neutralizing mAbs (2G12, 2F5, 
and 4E10) was tested for its ability to halt or delay rebound viremia during analytical 
treatment interruption (59,60). This antibody combination had limited effect on delaying 
virus rebound in these two studies. Of interest, only 2G12 appeared to consistently select for 
resistant viral strains within rebounding virus, suggesting that, of the three antibodies tested 
in the cocktail, it was the only one imposing a substantial antiviral effect. Two recent 
publications employed the CD4bs mAbs 3BNC117 and VRC01 in similar strategies to 
maintain suppression during ATI (61; Chun, NEJM, 2016 - pending). Both studies 
demonstrated a delay in time to virus rebound, but resistance was either present or developed 
in a high enough percentage of participants to indicate that the barrier to resistance to these 
single bnAb products is too low for them to serve as single agents for maintaining virus 
suppression.
Future directions for utilization of bnAbs to treat HIV-1 infection
Much remains unknown about the potential therapeutic usage of bnAbs. First and foremost, 
the actual in vivo antiviral mechanism (or mechanisms, as there may be more than one) is 
largely unknown. Do bnAbs act solely as entry inhibitors, or do they also act through their 
ability to opsonize and promote clearance of plasma virus? While it is clear that they can 
mediate ADCC and other effector mechanisms against virus-infected cells in vitro, what is 
the evidence that such mechanisms operate in vivo? The answer to this latter question will 
be crucial to the application of bnAbs in HIV cure strategies.
To date, the evidence suggests that basic antiviral drug therapy paradigms can be applied to 
therapy with bnAbs. Individual bnAbs will vary in potency and ease of generating 
resistance. However, as has been evident with all antiretrovirals, even the most broad and 
potent bnAb will probably prove ineffective as a single agent. Combinations of bnAbs with 
non-overlapping resistance patterns will likely be required to achieve an acceptable 
therapeutic and resistance profile for clinical development. Their long half-lives in vivo 
(approximately 14 days) make them attractive candidates for maintenance therapy (62). The 
introduction of long half-life mutations in the Fc region could further extend their in vivo 
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half-life (63), making them good candidates to combine with long-acting integrase inhibitors 
for maintenance therapy.
The development of mAbs to treat multiple human diseases has exploded in the last several 
years. It is therefore not surprising that antibody therapy against HIV infection is showing 
some promise. However, there remains much to learn and much to do before routine clinical 
use of bnAb therapy becomes a reality.
Non-neutralizing antibodies
Non-neutralizing Abs (non-nAbs) can play a significant role in protection from infections 
caused by smallpox (64,65), Sindbis (66,67), yellow fever (68), influenza virus (69), Ebola 
virus (70), and Epstein-Barr virus–related cancer manifestation (71), supporting the rationale 
that non-nAbs hold great potential to be harnessed by an antiviral vaccine regimen. Among 
the non-neutralizing functions, Ab can provide protection from viral infection by mediating 
virolysis, phagocytosis, or ADCC through recruitment of complement factors and/or 
engaging Fc-receptor (FcR)–bearing cells. Interestingly, the ability of antibody to mediate 
these polyfunctional activities has been correlated with vaccine-induced protection from 
SHIV in the NHP model (72) and linked to control of virus replication in HIV-1–infected 
elite controllers (73). ADCC responses that are mainly directed against the envelope 
glycoprotein have also been reported to control acute SIV infection in vaccinated NHP (74), 
to prevent HIV-1 mother-to-infant transmission (75), and to prevent disease progression in 
HIV-1–infected children (76) and adults (77–80). Furthermore, the importance of non-nAbs 
functions is also supported by the results of the RV144 trial, which was the only trial, out of 
six phase III clinical studies performed to date, that showed some level of efficacy (81).
Although anti-HIV-1 envelope-specific non-nAb functions have been correlated with 
reduced infection risk in RV144, the previously discussed sterilizing protective attributes 
observed for the bnAbs have thus far not been recapitulated when non-nAbs have been 
evaluated in passive protection studies using NHP models (91–94). Similarly, a subsequent 
NHP passive protection study conducted by Moog and collaborators indicated that the 
vaginal application of the non-nAbs 246-D and 4B3 directed against the principal immune-
domain on gp41 did not protect against high dose vaginal SHIV-162P3 challenge, whereas 
bnAb treatment protected a significant number of animals (92). Nonetheless, animals treated 
with the combination of non-nAbs were capable of controlling viremia relative to the 
infected controls. Recent studies evaluated the protective effects of A32 (94,95) and 7B2 
(93,97,98), non-nAbs directed against CD4 inducible epitopes (99) reported in the C1/C2 
region and the gp41 cluster I epitopes, respectively. The passive infusion studies conducted 
with these two mAbs demonstrated that they did not prevent infection from challenge with 
high dose SHIV1BaL, but were able to limit the number of transmitted/founder (T/F) HIV-1 
variants that established infection (93). A common limitation of these studies the reliance on 
the high dose challenge to evaluate the protective effect of non-nAbs. The amount of virus 
present in a typical high dose challenge far exceeds the average 0.42×104 copies/ml (range 
0.01–6.9×104) of virus present in the semen of untreated HIV-1 infected individuals (100). It 
is therefore possible that a protective non-nAb response, such as the ADCC observed in 
RV144, might be confined to prevention of transmission by a low dose challenge. This 
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possibility requires testing; however, the limited half-life of human mAbs upon infusion and 
restriction of the number of infusions that can be administered due to human mAb 
immunogenicity in NHP currently prevents performance of appropriate multiple low-dose 
challenge studies. A recent study aimed at circumventing these difficulties proved that it 
may be a difficult task. Fuchs and colleagues used a recombinant adeno-associated viral 
vector (rAAV) to deliver the 5L7 anti-SIV non-nAb directed against the envelope 
glycoproteins into rhesus monkeys before repeated marginal-dose challenge (101). One of 
the five animals treated with the rAAV-mAb did not become infected after six exposures; 
moreover, the peak as well as virus set point in the other animals were significantly lower 
than control groups in this study. The highest ADCC response was observed in the protected 
animal. Unfortunately, the anti-SIV mAb delivered by rAAV proved to be as immunogenic 
as the IgG in other studies, since 9 of the 12 animals tested positive for anti-IgG within 4 
weeks of administration of the rAAV-mAbs.
The experiments conducted thus far in NHP model using non-nAbs have not directly 
addressed the ability of this class of mAbs to perform as immune therapeutics and either 
control virus replication or impact the reservoir of latently infected cells, but they suggested 
that these mAbs can target infected cells by engaging the Fc-R-bearing cells. Therefore, 
similarly to nAbs, the non-nAbs can be a platform to generate molecules to be used as 
immune therapeutics in HIV-1 infection.
Bispecific antibodies and HIV-1 infection
Bispecific antibodies (bsAbs) are usually defined as molecules engineered to combine two 
antigen-binding variable fragments (Fv) of immunoglobulins in order to recognize two 
separate antigens (103). These molecules can therefore simultaneously interact with two 
different antigens presented on the surface of an individual cell or on two distinct cells. 
Since the first design of bsAb, a large body of literature now reports several combinations of 
bispecific and even trispecific Abs that can be used to diagnose or treat several human 
diseases including, but not limited to, infectious diseases and cancer (104).
The two major goals of designing these molecules have been to increase the breadth of 
antigens recognized by a monospecific mAb, and/or to engage antigen-expressing cells 
while simultaneously recruiting cytotoxic effector cells. Both types of constructs can be 
divided into two major classes depending upon the presence of the antibody Fc region or 
lack thereof.
In the pursuit of preventing and treating HIV-1 infection, bsAbs were initially designed to 
target free HIV-1 virions or HIV-1–infected cells based on gp41-specific Abs and 
demonstrated to mediate: 1) virus neutralization (105); 2) neutralization and ADCC (106); 
and 3) redirection of CD3+ T cells against HIV-1–infected or latently infected cells lines 
(107).
More recently, a different approach has increased the bsAbs neutralizing activity. Sun and 
collaborators designed a bsAb (iMabm36) by linking the anti-CD4 Ab ibalizumab (iMab) to 
two copies of the single domain CD4-inducible epitope m36Ab (108). The iMabm36 was 
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demonstrated to have higher neutralizing capacity than the m36 alone, and the capablity of 
neutralizing 83% of 118 pseudoviruses with an IC50<0.1µg/ml. A clinical trial is currently 
evaluating the potency of this bsAb in the current formulation for treating HIV-1 infection, 
and new proteins will be generated to target the pool of latently infected cells.
To increase the potency and breadth of bnAbs against HIV-1, four independent bsAbs were 
developed using the following combinations of bnAbs: VRC07x10e8, VRC07xPGT121, 
VRC07xPG9-16, and 10e8xPG9-16 (109). The most promising bispecific combination was 
represented by the VRC07xPG9-16 Ab that neutralized >84% pseudoviruses with 
IC50<1µg/ml and a 3– to 37-fold increased potency against 8 of 10 pseudoviruses included 
in this panel compared to the individual mAbs. Of note, this bispecific Ab neutralized 10 
pseudoviruses resistant to VRC07 (n=5) and PG9-16 (n=5) mAb when tested alone. 
Additional NHP studies revealed no difference in the pharmacokinetics between the parental 
and bispecific Abs, further indicating the advance in designing bsAbs that could be used for 
treatment and/or cure of HIV-1 infection.
Novel engineered bispecific molecules: BiTEs vs DARTS
Bispecific Abs have also been designed to recognize the antigenic structure of interest on the 
surface of target cells with one arm and engage functional receptors of the effector cells with 
the second arm. These new molecules lack the Fc region of the immunoglobulin. The first 
generation of these molecules was termed bispecific T cell engagers (BiTEs), and was 
developed to treat CD19+ B cell lymphoma. BiTEs consist of a protein composed of two 
single chain antibodies joined by a single polypeptide linker (110). This bs Ab used an anti-
CD19 arm linked to an anti-CD3 arm (bscCD19xCD3) that could provide potent 
engagement of the CD3+CD4+ and CD3+CD8+ T cell subsets directed against the human B 
cell lymphoma (111). Four additional BiTEs with different specificities have already been 
moved into phase I clinical studies to treat several malignancies (104). The second 
generation of BiTEs was named dual-affinity re-targeting (DART™) molecules (112). In the 
DART™, the heavy and light chains of the two antigen binding specificities of the diabody 
were separated into two separate polypeptide chains. The DART™ was additionally 
stabilized by the addition of a C-terminal disulfide bridge. A side-by-side in vitro 
comparison of CD19xCD3 BiTE and DART™ proteins based on the mouse anti-human 
CD3 and mouse anti-human CD19 mAb blinatumab indicated that the more rigid 
conformation of DART™ compared to BiTE proteins could provide a higher maximal 
activity level, half-maximal concentration, and induction of T cell activation (113). 
Prompted by these initial observations in developing immune therapeutics for cancer 
treatment, new BiTE and DART™ molecules have been designed to tackle the treatments of 
HIV-1 infection. The first HIV-specific BiTE molecule, VRC07- αCD3, was engineered 
based on the CD4bs-specific VRC07 bnAb (114) combined with an anti-CD3 arm to engage 
cytotoxic CD8 T cells (115). This protein was not only able to direct the cytotoxic activity of 
resting CD8+ T cells against a cell line that represent a model for constitutive and inducible 
HIV-1 expression, but also to recognize latently infected cells present in the peripheral blood 
mononuclear cells (PBMCs) from HIV-1 infected individuals under suppressive cART. This 
latter activity resulted in a decreased in vitro frequency of CD4+ T cells harboring provirus 
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after 48 hours in vitro incubation of the target CD4+ and effector CD8+ T cells in presence 
of the VRC07-αCD3.
Using the structure of DART™ molecules, several different HIV-1–specific DARTs have 
recently been generated and tested in vitro for their ability to recruit CD8+ cytotoxic T cells 
to recognize autologous infected cells. In the germinal study conducted by Sung and 
collaborators, the HIV-1–specific arm of the DART was based on the A32 and 7B2 non-
nAbs recognizing the highly conserved regions of the CD4i C1/C2 and gp41 cluster I 
envelope regions (116). The second study investigated an additional group of DARTs based 
on the N332-glycan PGT121 (117), V1/V2 PGT145 (118), CD4bs VRC01 (119,120), and 
MPER 10e8 (121) bnAbs generated using the same CD3 arm (122). All these molecules 
were demonstrated to have antiviral activity at nanogram levels and, therefore, suitable for in 
vivo utilization. Analyses of these molecules indicated that they can retain the breadth of the 
mAbs, can recruit resting CD8+ T cells to eliminate infected cells, and can reduce virus 
recovery when combined with latency-reversing agents capable of re-activating virus 
replication in PBMC samples obtained from HIV-1–infected individuals. Of interest, DARTs 
based on the bnAbs also retained their ability to neutralize the virus (122). In both studies, 
paired combinations of different DARTs did not reveal antagonistic effects and instead 
suggest that additive effects could be obtained.
It has been discussed that utilization of latency-reversing agents in combination with cART 
alone does not impact the size of the pool of latently infected cells due to several combined 
factors: 1) the concentration of cART may not be sufficient at the active site of virus 
replication in the germinal centers; 2) virus replication may not provide sufficient activating 
signals to the antigen-specific CD8 T cells; 3) escape mutant selected during the ontogeny of 
the adaptive immune responses may not be recognized by the existing cellular and humoral 
responses. The development of BiTEs and DARTs could overcome these hurdles, and future 
clinical evaluation of these molecules is already planned.
Future direction in the clinical applications of HIV-1 natural and engineered 
antibodies
Initial clinical studies revealed that utilization of individual bnAbs might face limitations 
due to the presence of circulating HIV-1 isolates already resistant to their recognition or to 
the appearance of escape mutants during mAb treatment. The absence of a single “magic 
bullet” to treat HIV-1 infection should not be a surprising observation, but it has spurred a 
new phase of pre-clinical research to address these initial concerns.
In vitro studies of BiTEs and DARTs have provided initial promising results, but more has to 
be done to address their half-life, safety, and efficacy in clinical settings. It seems reasonable 
to envision that the development of a cocktail of these molecules could also be necessary 
based on the potential presence of HIV-1 isolate that are already resistant to or may become 
resistant during treatment.
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Figure 1. Potential antiviral activity of neutralizing and non-neutralizing antibodies
Shown are potential sites of activity within the life cycle of HIV for neutralizing antibodies 
(opsonization or neutralization of free virus, ADCC of cells expressing HIV envelope during 
virus budding) or non-neutralizing antibodies (ADCC of cells during virus entry after 
envelope binding to CD4, ADCC of cells expressing HIV envelope during virus budding - if 
CD4 is encountered).
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